Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study

Documenti analoghi

• Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B‐Cell Lymphoma Preclinical Models
  di: Natsumi Kawasaki, et al.
  Pubblicazione: (2025)
• Final Results of a Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma
  di: Barry Paul, et al.
  Pubblicazione: (2025)
• A Real‐World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma in the United States
  di: Kim Saverno, et al.
  Pubblicazione: (2026)
• Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Mantle Cell Lymphoma: Real‐World Outcomes, Late Relapse Patterns, and Clinical Utility in the Chimeric Antigen Receptor T‐Cell Era
  di: Enver Aydilek, et al.
  Pubblicazione: (2026)
• Efficacy and Safety of Azacitidine Combined With Lisaftoclax in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome With Increased Blasts
  di: Shan Meng, et al.
  Pubblicazione: (2026)